Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
      Description

      This first-in-human study evaluates safety, tolerability and distribution of \[225Ac\] FPI-1966, \[111In\]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.

      Conditions
      Advanced Solid TumorHead and Neck Squamous Cell CarcinomaBladder CarcinomaSusceptible FGFR3 Genetic AlterationsFGFR3FGFR3 OverexpressionFGFR3 ReceptorFGFR3 Protein OverexpressionOvarian CancerColorectal CancerBreast CancerLiver CancerLung CancerGastric Cancer
      Talk to us
      TERMINATED
      Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
      Description

      This trial will assess the 6-month complete response rate and toxicity profile of oral dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3 mutations or over-expression who are ineligible for or refusing cystectomy.

      Conditions
      Bladder Cancer
      Talk to us
      RECRUITING
      Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
      Description

      A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

      Conditions
      Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, AdultFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationAdvanced Solid TumorsFGFR4 Gene MutationFGFR4 Gene FusionsFGF19 Gene AmplificationFGF19 Gene OverexpressionFGFR3 Gene FusionsLocally Advanced Unresectable Hepatocellular Carcinoma
      Talk to us